# TORCHLIGHT (NCT04085276)

> Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04085276
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Shanghai Junshi Bioscience Co., Ltd.
- Conditions: Triple-Negative Breast Cancer
- Interventions: JS001; Nab-Paclitaxel; Placebo; Nab-Paclitaxel
- Enrollment: 531
- Primary outcome: Progression-Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Intend to Treat patients.
- Primary outcome: PFS assessed by BICR using RECIST v1.1 in PD-L1 positive patients

## Commentary we found

- YouTube: 3
- Podcasts: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=torchlight-nct04085276